Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

29 October 2020
Pharma

Visiongain has published a new report on Meningococcal Vaccines Market Report : Forecasts by Serogroup (MenACWY, MenB/BC, MenC, MenAC and MenA), Vaccine Type (Conjugate, Polysaccharide and Subcapsular) and End User (Paediatric, Adults and Travellers). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Meningococcal Vaccines market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031.

Meningococcal diseases is caused by a type of bacteria, it can lead to an infection of the bloodstream or meningitis, or both, and can be life taking if not quickly treated. The meningococcal conjugate vaccines are very affective at protecting against four strains of the bacteria while the MenB vaccine protects against a fifth strain.

Two kinds of meningococcal vaccines are given to kids.
- The meningococcal conjugate vaccines
- The meningococcal B vaccines.

Vaccination with meningococcal conjugate is recommended when kids are of 11 or 12 years old with a booster given at the age of age of 16. For children 13 to 18 years of age who are not given vaccination yet.

Market Drivers
Increase in occurrences of meningococcal diseases rapidly has led to the development of meningococcal vaccine globally. Moreover, surge in immunization programs across the globe with regards to various disease including meningococcal bacteria has also boost the growth of the market.

Market Opportunities
Meningococcal vaccines are witnessing a considerable demand in line with a notable rise in their use for routine immunization. Growing use of meningococcal vaccines for immunization of special risk groups, including travellers or military personnel, and for recommended but not reimbursed immunization is fuelling gains in the market.

Regional Insights
North America dominated the Meningococcal vaccines market and recorded for a significant revenue share 2019, followed by Europe. Favourablesanctions and support from government and huge investments in R&D are some factors driving the North American market. For instance, in December 2019, NACI (National Advisory Committee on Immunization) published scientific information and recommendation on MenB-fHBP (bivalent factor-H binding protein meningococcal serogroup B) vaccine (Trumenba).

Asia Pacific market for Meningococcal vaccines is expected to grow at a noteworthy rate during the analysis period. The increasing paediatric population and growing initiatives by the government to fight the rising occurrence of the illness are paving the way towards the growth of meningococcal vaccines market in this region.

Competitive Landscape
Global meningococcal vaccines market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market. Complete competitive analysis and profiles of major meningococcal vaccine market players such as Bio-Manguinhos, Bio-Med Pvt. Limited, Chongqing Zhifei Biological Products Co., Ltd., GlaxoSmithKline Plc, Hualan Biological Engineering Inc., Incepta Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd, and Walvax Biotechnology Co., Ltd. are profiled in this report.

Recent Developments
The existence of a strong production in progress of meningococcal vaccines is expected to maintain a significant market share of the key players. For instance, Pfizer has established a new molecular entity named PF-06886992 for Serogroups ABCWY Meningococcal Infections which is currently in Phase II clinical trials.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

13 November 2020

Read

Visiongain Publishes Antihypertensive Drugs Market Report 2021-2031

Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese.

13 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever